- Investing Ideas
- /
- Polish Pharmaceuticals & Biotech Potentially Undervalued Companies
Polish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
8
Companies with a Value score of at least 3, ordered by Value score
8 companies
Bayer
Market Cap: zł27.1b
Operates as a life science company worldwide.
BAY
zł117.78
7D
-0.6%
1Y
2.4%
Read-Gene
Market Cap: zł68.9m
Engages in the detection, prevention, and treatment of various types of cancer.
RDG
zł5.84
7D
-2.3%
1Y
0%
Genomed Spólka Akcyjna
Market Cap: zł36.2m
Provides DNA sequencing and analysis, and diagnostics of congenital diseases in Poland.
GEN
zł27.40
7D
-0.7%
1Y
-2.1%
Novo Nordisk
Market Cap: zł1.7t
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
NVO
zł227.35
7D
15.2%
1Y
n/a
Stem Cells Spin
Market Cap: zł18.0m
Operates as a biotechnology company in Poland.
SCS
zł0.38
7D
6.1%
1Y
60.5%
Celon Pharma
Market Cap: zł1.2b
An integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations.
CLN
zł21.70
7D
-1.4%
1Y
-21.2%
Krka d. d
Market Cap: zł6.7b
A generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally.
KRK
zł928.00
7D
-0.4%
1Y
60.6%
Selvita
Market Cap: zł704.9m
Operates as a contract research organization worldwide.
SLV
zł38.40
7D
13.9%
1Y
-40.4%